Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bone Biologics Corp Director's Dealing 2022

Feb 28, 2022

35440_dirs_2022-02-28_9be54fd3-47cb-4a78-9830-2c609e4de91d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2022-01-01

Reporting Person: Frelick Jeff (Chief Executive Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-01 Employee Stock Option $3.72 A 50000 Acquired 2025-01-01 Common Stock (50000) Direct